Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 6:2022:9681235.
doi: 10.1155/2022/9681235. eCollection 2022.

Exploring the Effect of Enbrel Softgels on PWI Indicators in VCIND Patients

Lei Cui  1 , Pan Li  2 , Jingchen Zhang  1 , Xiaofang Li  1
Affiliations

Exploring the Effect of Enbrel Softgels on PWI Indicators in VCIND Patients

Lei Cui et al. J Healthc Eng. .

Retraction in

Abstract

Objective: To investigate the effect of Enbrel softgels on the head nuclear magnetic (PWI) indices in patients with vascular cognitive impairment-no dementia (vascular cognitive impairment-no dementia, VCIND).

Methods: Patients with confirmed VCIND hospitalized in the Department of Neurology of the Affiliated Hospital of Hebei University from April 2017 to April 2019 were included in the study, and they were divided into experimental and control groups (30 patients in each group) according to the difference of interventions. The PWI examination and neuropsychological assessment were performed at the beginning of the experiment, 12 w after treatment, and 48 w after treatment in the two groups. Score differences between the two groups and the preliminary demonstration of the clinical value of the MMSE and ADAS-Cog in the diagnosis of VCIND.

Results: (1) The difference in PWI positivity rate between the two groups at the beginning of the experiment was not statistically significant (P > 0.05); the PWI positivity rate in the experimental group at 12 W was significantly lower than that in the control group (P < 0.05); the difference in PWI positivity rate between the two groups at 48 W was not statistically significant (P < 0.05); (2) the MMSE scores of patients in the experimental group at 12 W and 48 W were higher than those in the control group, and the ADAS-Cog scores were lower than those in the control group (P < 0.05). (3) The diagnostic AUCs of MMSE and ADAS-Cog for VCIND were 0.7960 (95% CI = 0.6411-0.9508, P=0.0037) and 0.9291 (95% CI = 0.8390), respectively (95% CI = 0.8390-1.000, P < 0.0001).

Conclusion: The addition of Enbrel softgels to concomitant therapy in VCIND patients can lead to changes in their PWI imaging indicators, which in turn can have a significant impact on their neuropsychological indicators, and quantitative analysis scales such as the MMSE and ADAS-Cog can be considered for the diagnostic treatment of VCIND.

PubMed Disclaimer

Conflict of interest statement

The author declares that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Analysis of the changes in PWI indicators before and after the intervention in the two groups The difference in DWI positivity between the two groups at the beginning of the experiment was not statistically significant (P > 0.05), the DWI positivity rate in the experimental group was significantly lower than that in the control group at the 12th W of the experiment (P < 0.05), and the difference in DWI positivity between the two groups at the 48th week of the experiment was not statistically significant (P > 0.05).
Figure 2
Figure 2
Comparison of MMSE scores between the two groups before and after the intervention. The comparison showed that the difference between the two groups of patients' MMSE scores before the experiment was not statistically significant (P > 0.05), while the MMSE scores of the experimental group were higher than those of the control group at both the 12th W and 48th W of the experiment (P < 0.05) (a). Within the group, prepost variability was compared, with the experimental group (b) having higher MMSE scores at both the 12th W and 48th W than at the beginning of the experiment (P < 0.05), while the control group (c) did not have statistically significant differences in prepost comparisons (P > 0.05). # represents a statistically significant difference (Table 4).
Figure 3
Figure 3
Comparison of ADAS-cog scores between the two groups before and after the intervention. The comparison showed that the difference between the two groups in ADAS-cog scores before the experiment was not statistically significant (P > 0.05), and the ADAS-cog scores in the experimental group were lower than those in the control group at both the 12th W and 48th W of the experiment (P < 0.05) (a) Within-group, prepost variability was compared, with the experimental group (b) having lower ADAS-cog scores at both the 12th W and 48th W than at the beginning of the experiment (P < 0.05), while the control group (c) had no statistically significant differences in prepost comparisons (P > 0.05). # represents a statistically significant difference.
Figure 4
Figure 4
Analysis of the diagnostic value of MMSE and ADAS-cog scores for VCIND. The diagnostic AUC for VCIND was 0.7960 (95% CI = 0.6411–0.9508, P=0.0037) and 0.9291 (95% CI = 0.8390–1.000, P < 0.0001) for MMSE and ADAS-cog scores, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Iadecola C., Duering M., Hachinski V., et al. Vascular cognitive impairment and dementia. Journal of the American College of Cardiology . 2019;73(25):3326–3344. doi: 10.1016/j.jacc.2019.04.034. - DOI - PMC - PubMed
    1. Van der Flier W. M., Skoog I., Schneider J. A., et al. Vascular cognitive impairment. Nature Reviews Disease Primers . 2018;4(1):p. 18003. doi: 10.1038/nrdp.2018.3. - DOI - PubMed
    1. Sun M.-K. Potential therapeutics for vascular cognitive impairment and dementia. Current Neuropharmacology . 2018;16(7):1036–1044. doi: 10.2174/1570159X15666171016164734. - DOI - PMC - PubMed
    1. Frantellizzi V., Pani A., Ricci M., Locuratolo N., Fattapposta F., De Vincentis G. Neuroimaging in vascular cognitive impairment and dementia: a systematic review. Journal of Alzheimer’s Disease . 2020;73(4):1279–1294. doi: 10.3233/JAD-191046. - DOI - PubMed
    1. Farooq M. U., Min J., Goshgarian C., Gorelick P. B. Pharmacotherapy for vascular cognitive impairment. CNS Drugs . 2017;31(9):759–776. doi: 10.1007/s40263-017-0459-3. - DOI - PubMed

Publication types